Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Home Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

/ Publications

Share the Post

About the Author

AadiSite Support

Related Posts

Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Read More
Emma Reeve
UPDATE — Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit

Comments

Comments are closed.